Skip Nav Destination
Issues
1 October 2024
-
Cover Image
Cover Image
FZ-AD005 is an innovative ADC formed by a DLL3 antibody conjugated with Dxd via a novel Val-Ala linker. FZ-AD005 showed little ADCC activities due to Fc silencing mutations. FZ-AD005 exhibited excellent anti-tumor activities in PDX models and demonstrated a stable pharmacokinetic profile in monkeys. See graphical abstract and the full article on page 1367. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
First Disclosure
Review
Small Molecule Therapeutics
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar; Larry Yan; Fadia Qiryaqos; Lars D. Engstrom; Jade Laguer; Andrew Calinisan; Allan Hebbert; Laura Waters; Krystal Moya; Vickie Bowcut; Laura Vegar; John M. Ketcham; Anthony Ivetac; Christopher R. Smith; J. David Lawson; Lisa Rahbaek; Jeffrey Clarine; Natalie Nguyen; Barbara Saechao; Cody Parker; Adam J. Elliott; Darin Vanderpool; Leo He; Laura D. Hover; Julio Fernandez-Banet; Silvia Coma; Jonathan A. Pachter; Jill Hallin; Matthew A. Marx; David M. Briere; James G. Christensen; Peter Olson; Jacob Haling; Shilpi Khare
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
Gregory S. Parker; Julia I. Toth; Sarah Fish; Gabrielle Blanco; Taylor Kampert; Xiaoming Li; Linette Yang; Craig R. Stumpf; Kenneth Steadman; Aleksandar Jamborcic; Stephen Chien; Elizabeth Daniele; Alejandro Dearie; Geoffray Leriche; Simon Bailey; Peggy A. Thompson
Large Molecule Therapeutics
Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis
Sébastien Tabariès; Alma Robert; Anne Marcil; Binbing Ling; Mauro Acchione; Julie Lippens; Martine Pagé; Annie Fortin; Luc Meury; Mathieu Coutu; Matthew G. Annis; Charlotte Girondel; Julie Navarre; Maria Jaramillo; Anna N. Moraitis; Peter M. Siegel
Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
Amy E. Anderson; Kaustubh Parashar; Ke Jin; Julie Clor; Carlo E. Stagnaro; Urvi Vani; Jaskirat Singh; Ada Chen; Yihong Guan; Priyanka Talukdar; Pavithra Sathishkumar; Damie J. Juat; Hema Singh; Ritu Kushwaha; Xiaoning Zhao; Angelo Kaplan; Lisa Seitz; Matthew J. Walters; Ester Fernandez-Salas; Nigel P.C. Walker; Christine E. Bowman
The Vedotin Antibody–Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles
Haley D. Neff-LaFord; Sarah A. Carratt; Christopher Carosino; Nancy Everds; Kristen A. Cardinal; Steven Duniho; Melissa M. Schutten; Christopher Frantz; Christina Zuch de Zafra; Eric B. Harstad
Targeting Drug Resistance
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Anran Chen; Beom-Jun Kim; Aparna Mitra; Craig T. Vollert; Jonathan T. Lei; Diana Fandino; Meenakshi Anurag; Matthew V. Holt; Xuxu Gou; Jacob B. Pilcher; Matthew P. Goetz; Donald W. Northfelt; Susan G. Hilsenbeck; C. Gary Marshall; Marc L. Hyer; Robert Papp; Shou-Yun Yin; Carmine De Angelis; Rachel Schiff; Suzanne A.W. Fuqua; Cynthia X. Ma; Charles E. Foulds; Matthew J. Ellis
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds